Karri Burgner
Family · Sparks, NVNPI 1891845285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 26.8% of the total. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- GSK$669
- Pfizer$473
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$437
- Novo Nordisk$366
- plus $3K from 30 others
Across 2 payments — averaging $216.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$432
What the payments were for
- Food & beverage$8,305100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 126 | $2,229 |
| AstraZeneca | 40 | $1,522 |
| GSK | 25 | $669 |
| Pfizer | 31 | $473 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $437 |
| Novo Nordisk | 17 | $366 |
| Boehringer Ingelheim | 17 | $323 |
| Lilly USA, LLC | 13 | $257 |
| Merck | 12 | $225 |
| Abbott | 12 | $214 |
| Astellas Pharma US Inc | 9 | $183 |
| Biohaven Pharmaceuticals, Inc. | 15 | $149 |
| Bayer | 8 | $148 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $119 |
| Si-bone, Inc. | 1 | $114 |
| Dexcom, Inc. | 7 | $110 |
| Lundbeck LLC | 3 | $81 |
| Amgen | 4 | $74 |
| Corcept Therapeutics | 3 | $64 |
| Eisai Inc. | 3 | $61 |
| Verity Pharmaceuticals Inc. | 2 | $56 |
| Ironwood Pharmaceuticals, Inc | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Biocryst US Sales Co., LLC | 2 | $28 |
| Harmony Biosciences LLC | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Genentech USA, Inc. | 2 | $16 |
| Exact Sciences | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,305 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,016 |
| FarxigaDapagliflozin Propanediol | 11 | $7,262 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,640 |
| ValacyclovirValacyclovir Hcl | 25 | $1,987 |
| Gabapentin | 78 | $1,785 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,701 |
| Levothyroxine Sodium | 127 | $1,691 |
| Butalbital-Aspirin-CaffeineButalbital/Aspirin/Caffeine | 12 | $1,604 |
| Pantoprazole Sodium | 51 | $1,420 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $1,391 |
| Oxycodone Hcl | 39 | $1,379 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 64 | $1,288 |
| Potassium Chloride | 34 | $1,276 |
| Zolpidem Tartrate ErZolpidem Tartrate | 13 | $1,209 |
| Bupropion XlBupropion Hcl | 25 | $1,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,522 | $21,91837 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $42023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Sparks
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Kelly PapeshLas Vegas$28K
- Bernard BlanksLas Vegas$26K
- Kristy SolisHenderson$23K
- Lisa Hammargren-KuykendallReno$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.